|
1.4 Biologie - Technos
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
Lessons on trial design and transparency from ClinicalTrials.gov [BMJ Blogs]
|
|
|
|
|
|
For
instance, oncology had the lowest rate of results publication across
all disease areas, with only a fifth of all cancer studies published in a
journal. Is this low rate because of the high prevalence of small
sample sizes and non-randomised designs in this field? Or perhaps
because of the fact that so many cancer trials fail to show positive
outcomes? One thing is for certain: the evidence available in scientific
literature is largely incomplete, and could be distorted as well.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
FDA’s New Efforts to Advance Biotechnology Innovation [FDA]
|
|
|
|
|
|
FDA
is taking concrete and proactive steps to help ensure the safety of
plant and animal biotechnology products, while promoting innovation and
enhancing public and market confidence in FDA’s regulation of these
products at home and abroad.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
US nod for Alimta/Keytruda lung cancer combo [PharmaTimes]
|
|
|
|
|
|
The
combination was approved via the US Food and Drug Administration’s
accelerated approval pathway based on Phase II tumour response rate and
progression-free survival (PFS) data observed in a cohort of Merck's
KEYNOTE-021 study, and so its clinical benefit may still need to be
verified in confirmatory trials.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
|
5.5.15 ASCO (biopsies liquides)
|
|
|
|
5.5.4.5 ASCO (immunothérapies-CAR-T, thérapies cellulaires)
|
|
|
|
6.11 Patients
|
|
|
A Biotech Executive Faces End-Stage Cancer As A Patient [Forbes]
|
|
|
|
|
|
For
years, Michael Becker was one of the drug executives navigating swarms
of cancer doctors at the annual meeting of American Society of Clinical
Oncology, where 40,000 people gather every year to talk about the
hottest cancer-killing drugs. This year he came back, but it was very
different. This time he spoke to an audience of drug executives as a
patient living on borrowed time.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.3 DMP
|
|
|